11 September 2017 – partnership agreement
The company has announced a marketing agreement with QIAGEN, a world-leading provider of molecular testing solutions with over 500,000 customers, which will see the two companies combine to offer each other’s products to their respective customers. This is further vindication of ANGLE’s Parsortix system and the recent weakness in the company’s share price makes the shares a BUY.